{
    "nctId": "NCT01702571",
    "briefTitle": "A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment",
    "officialTitle": "A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2185,
    "primaryOutcomeMeasure": "Percentage of Participants With Adverse Events of Primary Interest (AEPIs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HER2-positive disease determined locally\n* Histologically or cytologically confirmed invasive breast cancer\n* Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced or metastatic setting must include both chemotherapy, alone or in combination with another agent, and an anti-HER2 agent, alone or in combination with another agent\n* Documented progression of incurable, unresectable, LABC, or mBC, defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy\n* Measurable and/or non-measurable disease\n* Left ventricular ejection fraction (LVEF) \\>/=50% by either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2\n* Adequate organ function\n* Use of highly effective contraception as defined by the protocol\n\nExclusion Criteria:\n\n* History of treatment with trastuzumab emtansine\n* Prior enrollment into a clinical study containing trastuzumab emtansine regardless of having received trastuzumab emtansine or not\n* Peripheral neuropathy of Grade \\>/= 3 per National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 4.0\n* History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer\n* History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to first study treatment except hormone therapy, which can be given up to 7 days prior to first study treatment; recovery of treatment-related toxicity consistent with other eligibility criteria\n* History of exposure to cumulative doses of anthracyclines\n* History of radiation therapy within 14 days of first study treatment. The participant must have recovered from any resulting acute toxicity (to Grade \\</=1) prior to first study treatment.\n* Metastatic central nervous system (CNS) disease only\n* Brain metastases which are symptomatic\n* History of a decrease in LVEF to less than (\\<) 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment\n* History of symptomatic CHF (New York Heart Association \\[NYHA\\] Classes II-IV) or serious cardiac arrhythmia requiring treatment\n* History of myocardial infarction or unstable angina within 6 months of first study treatment\n* Current dyspnea at rest due to complications of advanced malignancy or requirement for continuous oxygen therapy\n* Current severe, uncontrolled systemic disease (clinically significant cardiovascular, pulmonary, or metabolic disease)\n* Pregnancy or lactation\n* Currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus\n* History of intolerance (such as Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins or any component of the product",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}